JP2012533519A - 骨髄細胞外マトリックス抽出物およびその治療上の使用 - Google Patents
骨髄細胞外マトリックス抽出物およびその治療上の使用 Download PDFInfo
- Publication number
- JP2012533519A JP2012533519A JP2012515517A JP2012515517A JP2012533519A JP 2012533519 A JP2012533519 A JP 2012533519A JP 2012515517 A JP2012515517 A JP 2012515517A JP 2012515517 A JP2012515517 A JP 2012515517A JP 2012533519 A JP2012533519 A JP 2012533519A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- extracellular matrix
- bone marrow
- hematopoietic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 title claims description 51
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 title claims description 51
- 210000001185 bone marrow Anatomy 0.000 title claims description 51
- 210000002744 extracellular matrix Anatomy 0.000 title claims description 51
- 239000000284 extract Substances 0.000 title claims description 26
- 230000001225 therapeutic effect Effects 0.000 title description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims abstract description 97
- 238000000034 method Methods 0.000 claims abstract description 43
- 230000007774 longterm Effects 0.000 claims abstract description 15
- 210000004027 cell Anatomy 0.000 claims description 113
- 239000003102 growth factor Substances 0.000 claims description 19
- 108010002386 Interleukin-3 Proteins 0.000 claims description 15
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 14
- 241000124008 Mammalia Species 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 230000002435 cytoreductive effect Effects 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 7
- 210000000066 myeloid cell Anatomy 0.000 claims description 7
- 108010002352 Interleukin-1 Proteins 0.000 claims description 6
- 208000007502 anemia Diseases 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 6
- 108020001507 fusion proteins Proteins 0.000 claims description 6
- 102000037865 fusion proteins Human genes 0.000 claims description 6
- 230000002062 proliferating effect Effects 0.000 claims description 5
- 210000002798 bone marrow cell Anatomy 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 208000003747 lymphoid leukemia Diseases 0.000 claims description 2
- 238000010899 nucleation Methods 0.000 claims description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 4
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 2
- 230000009033 hematopoietic malignancy Effects 0.000 claims 2
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 abstract description 52
- 230000004069 differentiation Effects 0.000 abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- 201000010099 disease Diseases 0.000 abstract description 4
- 230000007123 defense Effects 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 19
- 230000035755 proliferation Effects 0.000 description 16
- 238000002054 transplantation Methods 0.000 description 16
- 210000003995 blood forming stem cell Anatomy 0.000 description 14
- 210000005087 mononuclear cell Anatomy 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 238000001727 in vivo Methods 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 102100039064 Interleukin-3 Human genes 0.000 description 11
- 230000012010 growth Effects 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 10
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 9
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 9
- 210000000601 blood cell Anatomy 0.000 description 9
- 238000004113 cell culture Methods 0.000 description 9
- 230000003394 haemopoietic effect Effects 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 208000024908 graft versus host disease Diseases 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 210000005259 peripheral blood Anatomy 0.000 description 6
- 239000011886 peripheral blood Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 102000015696 Interleukins Human genes 0.000 description 5
- 108010063738 Interleukins Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000010322 bone marrow transplantation Methods 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 230000004936 stimulating effect Effects 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 102000000589 Interleukin-1 Human genes 0.000 description 4
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 4
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 230000011132 hemopoiesis Effects 0.000 description 4
- 229940047122 interleukins Drugs 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 3
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 208000009329 Graft vs Host Disease Diseases 0.000 description 3
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 3
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 229960002092 busulfan Drugs 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 108700014844 flt3 ligand Proteins 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 210000000777 hematopoietic system Anatomy 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 108010044426 integrins Proteins 0.000 description 3
- 102000006495 integrins Human genes 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000002536 stromal cell Anatomy 0.000 description 3
- 208000032467 Aplastic anaemia Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000019838 Blood disease Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000015617 Janus Kinases Human genes 0.000 description 2
- 108010024121 Janus Kinases Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 2
- 238000011789 NOD SCID mouse Methods 0.000 description 2
- 206010033661 Pancytopenia Diseases 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- 101150052863 THY1 gene Proteins 0.000 description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- -1 cell culture fluid Chemical compound 0.000 description 2
- 208000024389 cytopenia Diseases 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000002825 functional assay Methods 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 208000014951 hematologic disease Diseases 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 208000018706 hematopoietic system disease Diseases 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000003593 megakaryocyte Anatomy 0.000 description 2
- 210000003924 normoblast Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000002629 repopulating effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000011476 stem cell transplantation Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 108091008578 transmembrane receptors Proteins 0.000 description 2
- 102000027257 transmembrane receptors Human genes 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 108010027122 ADP-ribosyl Cyclase 1 Proteins 0.000 description 1
- 102000018667 ADP-ribosyl Cyclase 1 Human genes 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 102000013925 CD34 antigen Human genes 0.000 description 1
- 108050003733 CD34 antigen Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102100025470 Carcinoembryonic antigen-related cell adhesion molecule 8 Human genes 0.000 description 1
- 206010068051 Chimerism Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 102000028180 Glycophorins Human genes 0.000 description 1
- 108091005250 Glycophorins Proteins 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 description 1
- 101000914320 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 8 Proteins 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 208000001019 Inborn Errors Metabolism Diseases 0.000 description 1
- 102100032817 Integrin alpha-5 Human genes 0.000 description 1
- 108010041014 Integrin alpha5 Proteins 0.000 description 1
- 108010042918 Integrin alpha5beta1 Proteins 0.000 description 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 210000002361 Megakaryocyte Progenitor Cell Anatomy 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102100038081 Signal transducer CD24 Human genes 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 206010060872 Transplant failure Diseases 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002338 cryopreservative effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000011124 ex vivo culture Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 210000002360 granulocyte-macrophage progenitor cell Anatomy 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 208000034737 hemoglobinopathy Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000016245 inborn errors of metabolism Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000015978 inherited metabolic disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 231100001023 lymphopenia Toxicity 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000003039 myelosuppressive effect Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000005009 osteogenic cell Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 101710135378 pH 6 antigen Proteins 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 238000012247 phenotypical assay Methods 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000003651 pro-proliferative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011155 quantitative monitoring Methods 0.000 description 1
- 238000009118 salvage therapy Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000033772 system development Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 230000006444 vascular growth Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3608—Bone, e.g. demineralised bone matrix [DBM], bone powder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3633—Extracellular matrix [ECM]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Botany (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Developmental Biology & Embryology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21818209P | 2009-06-18 | 2009-06-18 | |
| US61/218,182 | 2009-06-18 | ||
| PCT/EP2010/058675 WO2010146177A1 (en) | 2009-06-18 | 2010-06-18 | Bone marrow extracellular matrix extract and therapeutic use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012533519A true JP2012533519A (ja) | 2012-12-27 |
| JP2012533519A5 JP2012533519A5 (enExample) | 2013-05-30 |
Family
ID=42556414
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012515517A Pending JP2012533519A (ja) | 2009-06-18 | 2010-06-18 | 骨髄細胞外マトリックス抽出物およびその治療上の使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20120065620A1 (enExample) |
| EP (1) | EP2442837B1 (enExample) |
| JP (1) | JP2012533519A (enExample) |
| CN (1) | CN102802686A (enExample) |
| WO (1) | WO2010146177A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12472282B2 (en) | 2018-03-30 | 2025-11-18 | University Of Rochester | Bioengineered wharton's jelly derived extracellular matrix |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105395570A (zh) * | 2015-09-23 | 2016-03-16 | 广东颐养抗衰老研究院 | 一种用于治疗老年性白血病的组合物 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000500372A (ja) * | 1995-11-20 | 2000-01-18 | フィディア アドヴァンスド バイオポリマーズ ソシエタ ア レスポンサビリタ リミタータ | 結合組織細胞に部分的又は完全に分化した骨髄幹細胞の有効培養物及びヒアルロン酸誘導体より成る三次元の生体親和性で且つ生分解性のマトリックスから構成される生物学的物質 |
| JP2002535981A (ja) * | 1999-02-04 | 2002-10-29 | テクニオン リサーチ アンド デブェロップメント ファウンデーション リミテド | 造血幹細胞および／または前駆細胞を維持および増加するための方法および装置 |
| WO2005009498A2 (en) * | 2003-07-17 | 2005-02-03 | Boston Scientific Limited | Decellularized bone marrow extracellular matrix |
| JP2005192521A (ja) * | 2004-01-09 | 2005-07-21 | Hiroko Sato | 部分分解重合性タンパク質からなる造血幹細胞を含む未熟な血液細胞（ｈｓｃ）の増殖促進用支持体およびその支持体を使用したｈｓｃの製造方法。 |
| JP2007535486A (ja) * | 2003-05-07 | 2007-12-06 | ラ ホーヤ インスティチュート フォー モレキュラー メディシン | 高分子量のヒアルロン酸を用いた内因性又は埋め込まれた又は移植された幹細胞の機能回復を促進するための方法 |
| WO2007148332A1 (en) * | 2006-06-22 | 2007-12-27 | Yeda Resaerch And Development Co. Ltd | Catecholamine receptor modulation |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5674750A (en) | 1995-05-19 | 1997-10-07 | T. Breeders | Continuous selective clonogenic expansion of relatively undifferentiated cells |
| US5925567A (en) | 1995-05-19 | 1999-07-20 | T. Breeders, Inc. | Selective expansion of target cell populations |
| WO2003038048A2 (en) * | 2001-10-30 | 2003-05-08 | The United States Of America As Represented By The Secretary Of The Navy | Ex-vivo rescue of transplantable hematopoietic stem cells following myeloablative injury |
| ES2538305T3 (es) * | 2004-10-25 | 2015-06-18 | Cellerant Therapeutics, Inc. | Métodos para expandir poblaciones de células mieloides y usos de las mismas |
| EP1965812A4 (en) * | 2005-11-08 | 2010-02-24 | Georgia Tech Res Inst | AZELLULARIZED BIOLOGICAL MATERIAL FROM EMBRYONAL STEM CELLS |
| JP5341525B2 (ja) * | 2006-02-14 | 2013-11-13 | セルラント セラピューティクス，インコーポレイティド | 造血幹細胞の生着を増強するための方法および組成物 |
| CN101062428A (zh) * | 2006-04-24 | 2007-10-31 | 中国人民解放军军事医学科学院野战输血研究所 | 一种组织工程化皮肤的构建方法与应用 |
| DE102006060247A1 (de) * | 2006-09-15 | 2008-03-27 | Ossacur Ag | Differenzierung von Stammzellen |
| WO2009072990A1 (en) * | 2007-12-06 | 2009-06-11 | Agency For Science, Technology And Research | Method for extracellular matrix mediated differentiation and proliferation of stem cells |
| WO2009080794A1 (en) * | 2007-12-21 | 2009-07-02 | Mc2 Cell Aps | Method for preparing cell-specific extracellular matrices |
-
2010
- 2010-06-18 JP JP2012515517A patent/JP2012533519A/ja active Pending
- 2010-06-18 CN CN2010800267188A patent/CN102802686A/zh active Pending
- 2010-06-18 WO PCT/EP2010/058675 patent/WO2010146177A1/en not_active Ceased
- 2010-06-18 EP EP10724868.4A patent/EP2442837B1/en not_active Not-in-force
- 2010-06-18 US US13/320,872 patent/US20120065620A1/en not_active Abandoned
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000500372A (ja) * | 1995-11-20 | 2000-01-18 | フィディア アドヴァンスド バイオポリマーズ ソシエタ ア レスポンサビリタ リミタータ | 結合組織細胞に部分的又は完全に分化した骨髄幹細胞の有効培養物及びヒアルロン酸誘導体より成る三次元の生体親和性で且つ生分解性のマトリックスから構成される生物学的物質 |
| JP2002535981A (ja) * | 1999-02-04 | 2002-10-29 | テクニオン リサーチ アンド デブェロップメント ファウンデーション リミテド | 造血幹細胞および／または前駆細胞を維持および増加するための方法および装置 |
| JP2007535486A (ja) * | 2003-05-07 | 2007-12-06 | ラ ホーヤ インスティチュート フォー モレキュラー メディシン | 高分子量のヒアルロン酸を用いた内因性又は埋め込まれた又は移植された幹細胞の機能回復を促進するための方法 |
| WO2005009498A2 (en) * | 2003-07-17 | 2005-02-03 | Boston Scientific Limited | Decellularized bone marrow extracellular matrix |
| JP2005192521A (ja) * | 2004-01-09 | 2005-07-21 | Hiroko Sato | 部分分解重合性タンパク質からなる造血幹細胞を含む未熟な血液細胞（ｈｓｃ）の増殖促進用支持体およびその支持体を使用したｈｓｃの製造方法。 |
| WO2007148332A1 (en) * | 2006-06-22 | 2007-12-27 | Yeda Resaerch And Development Co. Ltd | Catecholamine receptor modulation |
Non-Patent Citations (2)
| Title |
|---|
| JPN6014017812; Ｒｅｇｅｎ． Ｍｅｄ． Ｖｏｌ．２， Ｎｏ．４, 2007, ｐ．３８３-３９０ * |
| JPN6014017813; ＳＴＥＭ ＣＥＬＬＳ Ｖｏｌ．２２， Ｎｏ．４, 2004, ｐ．５４４-５５５ * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12472282B2 (en) | 2018-03-30 | 2025-11-18 | University Of Rochester | Bioengineered wharton's jelly derived extracellular matrix |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010146177A1 (en) | 2010-12-23 |
| US20120065620A1 (en) | 2012-03-15 |
| EP2442837B1 (en) | 2014-08-20 |
| CN102802686A (zh) | 2012-11-28 |
| EP2442837A1 (en) | 2012-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Andrews et al. | CD34+ marrow cells, devoid of T and B lymphocytes, reconstitute stable lymphopoiesis and myelopoiesis in lethally irradiated allogeneic baboons | |
| Fajardo-Orduña et al. | Hematopoietic support capacity of mesenchymal stem cells: biology and clinical potential | |
| Zhou et al. | Development and function of myeloid-derived suppressor cells generated from mouse embryonic and hematopoietic stem cells | |
| Keyser et al. | Comparison of mesenchymal stem cells from different tissues to suppress T-cell activation | |
| US7790458B2 (en) | Material and methods for the growth of hematopoietic stem cells | |
| CA2565581C (en) | Apparatus and methods for amplification of blood stem cell numbers | |
| Ehring et al. | Expansion of HPCs from cord blood in a novel 3D matrix | |
| Lo Iacono et al. | Wharton’s jelly mesenchymal stromal cells as a feeder layer for the ex vivo expansion of hematopoietic stem and progenitor cells: a review | |
| US20100151569A1 (en) | Method of producing a population of cells | |
| Madlambayan et al. | Clinically relevant expansion of hematopoietic stem cells with conserved function in a single-use, closed-system bioprocess | |
| Yamaguchi et al. | Ex vivo expansion of human UC blood primitive hematopoietic progenitors and transplantable stem cells using human primary BM stromal cells and human AB serum | |
| Psatha et al. | Optimizing autologous cell grafts to improve stem cell gene therapy | |
| Haylock et al. | Expansion of umbilical cord blood for clinical transplantation | |
| Kim et al. | Ex Vivo Expansion of Human Umbilical Cord Blood CD34+ Cells in a Collagen Bead—Containing 3-Dimensional Culture System | |
| Mukhopadhyay et al. | Hematopoietic stem cells: clinical requirements and developments in ex-vivo culture | |
| CN114402065A (zh) | 低密度细胞培养 | |
| AU2008277391A1 (en) | Culture for expanding stem cells ex-vivo | |
| WO1991018972A1 (en) | Culturing bone marrow cells for adoptive immunotherapy | |
| EP2442837B1 (en) | Bone marrow extracellular matrix extract and therapeutic use thereof | |
| CN114990063B (zh) | 促进造血干祖细胞迁移、归巢和植入的组合物及其应用 | |
| AU661709B2 (en) | Yolk sac stem cells | |
| CA3198833A1 (en) | Production of megakaryocytes and platelets in a co-culture system | |
| JP2006067858A (ja) | 共培養による造血幹細胞の増幅方法 | |
| EP1673445B1 (en) | Blood products from mesenchymal stem cells | |
| Kraft et al. | Hematopoietic stem cells: basic science to clinical applications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130325 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130325 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140507 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140924 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141006 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20141111 |